Arch Biopartners Inc ACHFF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACHFF is a good fit for your portfolio.
News
-
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
-
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
-
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
-
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
-
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
-
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
-
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury
Trading Information
- Previous Close Price
- $1.41
- Day Range
- $1.35–1.41
- 52-Week Range
- $0.72–1.88
- Bid/Ask
- $1.34 / $1.38
- Market Cap
- $84.92 Mil
- Volume/Avg
- 7,300 / 22,385
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
- Website
- https://www.archbiopartners.com
Comparables
Valuation
Metric
|
ACHFF
|
NYKD
|
HLVX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 2.48 | 2.26 |
Price/Sales | — | 29.11 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ACHFF
NYKD
HLVX
Financial Strength
Metric
|
ACHFF
|
NYKD
|
HLVX
|
---|---|---|---|
Quick Ratio | 0.10 | 7.91 | 10.37 |
Current Ratio | 0.11 | 8.04 | 10.62 |
Interest Coverage | −4.19 | −235.75 | −54.72 |
Quick Ratio
ACHFF
NYKD
HLVX
Profitability
Metric
|
ACHFF
|
NYKD
|
HLVX
|
---|---|---|---|
Return on Assets (Normalized) | −89.86% | −19.18% | −34.03% |
Return on Equity (Normalized) | — | −26.31% | −42.52% |
Return on Invested Capital (Normalized) | — | −30.96% | −38.62% |
Return on Assets
ACHFF
NYKD
HLVX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Czncrmxsf | Wwkp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Flhsckkl | Xqwyd | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jtcjrnbd | Rmfgs | $97.8 Bil | |
MRNA
| Moderna Inc | Lzxwthv | Jbxs | $41.3 Bil | |
ARGX
| argenx SE ADR | Byhqgxnh | Gkjh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mydqpgglc | Bmf | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jfgsyvmh | Fwshn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hnwryfcp | Ntdgtp | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ytlxzfshh | Cycgy | $12.5 Bil | |
INCY
| Incyte Corp | Swwxjtc | Shkmjvk | $11.6 Bil |